Tirzepatide reduced sleep apnea with and without CPAP use. We review sleep apnea, the new studies, drug side effects, and cost issues.
Eli Lilly announced on April 17, 2024, that tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63%, meeting all primary and key secondary endpoints in two phase 3 clinical trials.
Let's review what sleep apnea is, the new studies, the potential side effects of the drug, and cost issues.
In the past, it was unclear if colon cancer screening was worth doing for people over 75. A new study shows that it is often life-saving.
How do you view solar eclipses and understand what you are seeing?
A research participant died during a study on depression. An FDA audit found many serious errors and sent a warning letter and the study was put on hold.
Medicare is prohibited from paying for weight-loss treatments. But Wegovy® now has an FDA-approved indication beyond weight loss and can now qualify for payment under Part D. Review of FDA approval, Medicare part D, and the SELECT trial the approval was based on.
Healthy Insight, LLC © . All rights reserved.